PCSK9 and familial hyperaldosteronism: Lappegård et al. (2018) firstly explored HDL-CEC on lipoprotein apheresis and subsequently on PCSK9 inhibition with evolocumab in FH subjects, finding no changes in HDL-CEC during PCSK9-i treatment. However, the sample size in this study was particularly small (three subjects) and the ex vivo CEC evaluation was performed in a different cellular model and with a different methodological assay, thus implying the need of a careful interpretation of their results.